Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in non-small cell lung cancer (NSCLC) patients, it is still controversial about how to combine EGFR-TKI with chemotherapy and other targeted drugs. We have made a summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab in this review and aimed to find the optimal therapeutic strategy for NSCLC patients with EGFR mutation.
目前表皮生长因子酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）已广泛应用于非小细胞肺癌（non-small cell lung cancer, NSCLC）患者，但如何将EGFR-TKI与化疗及其他靶向药物结合仍存在诸多争议。本综述阐述了EGFR-TKI与化疗的3种不同联合模式：前后序贯治疗、同步联合治疗及间插联合治疗；分析EGFR-TKI与贝伐珠单抗联合治疗的优劣性；初步探讨了EGFR突变患者的最佳治疗模式。